Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care
D Patoulias, T Koufakis, I Ruža… - Pragmatic and …, 2024 - Taylor & Francis
Obesity is currently considered a global epidemic, with rising prevalence worldwide and
rather pessimistic projections. Based on its close interconnection with various co …
rather pessimistic projections. Based on its close interconnection with various co …
[HTML][HTML] Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism—A Narrative Review
Z Szekeres, A Nagy, K Jahner, E Szabados - International Journal of …, 2024 - mdpi.com
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel antihyperglycemic agents.
By acting through the central nervous system, they increase satiety and reduce food intake …
By acting through the central nervous system, they increase satiety and reduce food intake …
[HTML][HTML] Glucagon-like Receptor-1 Agonists for Obesity: Weight Loss Outcomes, Tolerability, Side Effects, and Risks
W Ghusn, MD Hurtado - Obesity Pillars, 2024 - Elsevier
Background This review investigates the side effects of glucagon-like peptide-1 receptor
agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for …
agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for …
[HTML][HTML] Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
DM Williams, BA Alberts, A Sharaf, G Sharaf, SC Bain… - Diabetes Therapy, 2024 - Springer
Methods People with T2D initiated on oral semaglutide in secondary care diabetes clinics at
two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons …
two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons …
Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis
G Dorneles, E Algeri, G Lauterbach… - Experimental and …, 2024 - thieme-connect.com
Background To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide
treatment in overweight or obese patients without type 2 diabetes. Methods Randomized …
treatment in overweight or obese patients without type 2 diabetes. Methods Randomized …
[PDF][PDF] Obesity Pillars
W Ghusn, MD Hurtado - sochob.cl
Background: This review investigates the side effects of glucagon-like peptide-1 receptor
agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for …
agonists (GLP-1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for …